Prostate cancer patients have been offered hope after scientists at Newcastle University have identified a new group of molecules that could be targeted to slow tumour growth.
A 3-year research project involved the use of an advanced screening technique called RNA-sequencing, which found that hundreds of genes were affected by testosterone, according to findings published in EBioMedicine. Of the 700 genes identified, an important set that added glycans to the surface of prostate cancer cells was found. This group of genes has never been investigated before.
Targeting glycans
Treatments targeting glycan sugar groups have been developed for other types of the illness, such as breast cancer. It is hoped these treatments could also be used for prostate cancer. Results of the research, suggest that testosterone changes glycans to make cancer cells more likely to survive, grow and spread to other parts of the body.
Scientists say there is the potential to target these glycans which could stop the growth and spread of tumours and save lives. Dr Jennifer Munkley, Research Associate at the Institute of Genetic Medicine, Newcastle University, co-led the three-year research project with Professor David Elliott.
“Our findings are very significant for future treatments as they identify a new group of molecules in prostate cancer which could be targeted therapeutically.
“Now we have identified these glycans we will be able to develop strategies to inhibit them and help patients with this condition.
“Treatments targeting glycan sugar groups have been developed for other types of the illness, such as breast cancer. Our results mean these treatments could also be used for prostate cancer.”
Glycans have the potential to be used as part of a diagnostic test to help doctors decide which prostate cancers need treatment.
Reciprocal gene expression signatures identify a core set of clinically relevant androgen-regulated target genes
(A) RNA-Seq expression analysis of LNCaP cells treated with or without 10 nM R1881 (a synthetic androgen) for 24 h in triplicate, and of 7 PCa patient prostate biopsies before and after androgen ablation therapy (ADT). (B) Scatter plot of reciprocally regulated genes between the two datasets. (C) Gene Ontology (GO) analysis of the reciprocally regulated genes identified 72 terms with significant gene enrichment.
Most common cancer for males in UK
One in eight will be diagnosed with the condition. It is the most common cancer in UK males, and there is a need to identify how the disease progresses and for treatment options to be established. Researchers at Newcastle University used a technique, called RNA-sequencing, to identify the new set of genes that are important. The genes identified may provide novel ways the disease can be monitored in patients to predict the most aggressive prostate cancers that need to be treated.
Source – Newcastle University
[box type=”shadow” align=”alignleft” ]Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries LW, Leung HY, Robson CN, Mills IG, Rajan P, Elliott DJ. (2016)
Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability.
EBioMedicine 8:103-16. [
article][/fusion_text][/fusion_builder_column_inner][/fusion_builder_row_inner][/fusion_builder_column]
Source-
Prostate cancer patients have been offered hope after scientists at Newcastle University have identified a new group of molecules that could be targeted to slow tumour growth.
A 3-year research project involved the use of an advanced screening technique called RNA-sequencing, which found that hundreds of genes were affected by testosterone, according to findings published in EBioMedicine. Of the 700 genes identified, an important set that added glycans to the surface of prostate cancer cells was found. This group of genes has never been investigated before.
Targeting glycans
Treatments targeting glycan sugar groups have been developed for other types of the illness, such as breast cancer. It is hoped these treatments could also be used for prostate cancer. Results of the research, suggest that testosterone changes glycans to make cancer cells more likely to survive, grow and spread to other parts of the body.
Scientists say there is the potential to target these glycans which could stop the growth and spread of tumours and save lives. Dr Jennifer Munkley, Research Associate at the Institute of Genetic Medicine, Newcastle University, co-led the three-year research project with Professor David Elliott.
Glycans have the potential to be used as part of a diagnostic test to help doctors decide which prostate cancers need treatment.
Reciprocal gene expression signatures identify a core set of clinically relevant androgen-regulated target genes
(A) RNA-Seq expression analysis of LNCaP cells treated with or without 10 nM R1881 (a synthetic androgen) for 24 h in triplicate, and of 7 PCa patient prostate biopsies before and after androgen ablation therapy (ADT). (B) Scatter plot of reciprocally regulated genes between the two datasets. (C) Gene Ontology (GO) analysis of the reciprocally regulated genes identified 72 terms with significant gene enrichment.
Most common cancer for males in UK
One in eight will be diagnosed with the condition. It is the most common cancer in UK males, and there is a need to identify how the disease progresses and for treatment options to be established. Researchers at Newcastle University used a technique, called RNA-sequencing, to identify the new set of genes that are important. The genes identified may provide novel ways the disease can be monitored in patients to predict the most aggressive prostate cancers that need to be treated.
Source – Newcastle University
[box type=”shadow” align=”alignleft” ]Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries LW, Leung HY, Robson CN, Mills IG, Rajan P, Elliott DJ. (2016) Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. EBioMedicine 8:103-16. [article][/fusion_text][/fusion_builder_column_inner][/fusion_builder_row_inner][/fusion_builder_column]Source-
Related Posts
RNA sequencing reveals functional chimeric mRNAs in mammalian immunity
Atlas of the brain’s striatum could guide researchers to new drug treatments
Immune cells offer insights on billion-dollar virus
A functionally integrated cross-tissue alternative splicing program during short-term calorie restriction
Dietary oxidized plant sterol shifts macrophage state to fuel aortic inflammation
Unlocking the past – new method helps gain insights into old tissue
Novel AI model trained on RNA-Seq data accurately detects key gene mutations and predicts biomarkers across 32 cancer types
Transcriptomic aging clock reveals age-related molecular patterns in opioid dependence
RNA sequencing helps predict stem cell transplant benefit in pediatric AML
Protein ‘switch’ determines whether liposarcoma cells will become aggressive
Precursor tRNAs sense temperature changes: heat stress-induced capped pre-tRNAs suppress protein synthesis
Ketamine increases neuroplasticity in female mice but not in males
Somatic mutations linked to vascular damage in progeria
Scientists map dormant cancer cells’ hideouts, opening new targets for treatment
Soluble signals released by neighboring cells direct how the human kidney is built
Genetics influence how cancer arises – and how it evolves
RNA-based testing uncovers extraordinary diversity in mutations driving lung cancer
Study offers new insights into why ex-smokers remain at elevated risk of lung disease
Learning the grammar of gene regulation
New findings could transform new treatment for rare brain tumor astroblastoma
Prostate cancer patients have been offered hope after scientists at Newcastle University have identified a new group of molecules that could be targeted to slow tumour growth.
A 3-year research project involved the use of an advanced screening technique called RNA-sequencing, which found that hundreds of genes were affected by testosterone, according to findings published in EBioMedicine. Of the 700 genes identified, an important set that added glycans to the surface of prostate cancer cells was found. This group of genes has never been investigated before.
Targeting glycans
Treatments targeting glycan sugar groups have been developed for other types of the illness, such as breast cancer. It is hoped these treatments could also be used for prostate cancer. Results of the research, suggest that testosterone changes glycans to make cancer cells more likely to survive, grow and spread to other parts of the body.
Scientists say there is the potential to target these glycans which could stop the growth and spread of tumours and save lives. Dr Jennifer Munkley, Research Associate at the Institute of Genetic Medicine, Newcastle University, co-led the three-year research project with Professor David Elliott.
Glycans have the potential to be used as part of a diagnostic test to help doctors decide which prostate cancers need treatment.
Reciprocal gene expression signatures identify a core set of clinically relevant androgen-regulated target genes
(A) RNA-Seq expression analysis of LNCaP cells treated with or without 10 nM R1881 (a synthetic androgen) for 24 h in triplicate, and of 7 PCa patient prostate biopsies before and after androgen ablation therapy (ADT). (B) Scatter plot of reciprocally regulated genes between the two datasets. (C) Gene Ontology (GO) analysis of the reciprocally regulated genes identified 72 terms with significant gene enrichment.
Most common cancer for males in UK
One in eight will be diagnosed with the condition. It is the most common cancer in UK males, and there is a need to identify how the disease progresses and for treatment options to be established. Researchers at Newcastle University used a technique, called RNA-sequencing, to identify the new set of genes that are important. The genes identified may provide novel ways the disease can be monitored in patients to predict the most aggressive prostate cancers that need to be treated.
Source – Newcastle University
[box type=”shadow” align=”alignleft” ]Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries LW, Leung HY, Robson CN, Mills IG, Rajan P, Elliott DJ. (2016) Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. EBioMedicine 8:103-16. [article][/fusion_text][/fusion_builder_column_inner][/fusion_builder_row_inner][/fusion_builder_column]Source-
Related Posts
RNA sequencing reveals functional chimeric mRNAs in mammalian immunity
Atlas of the brain’s striatum could guide researchers to new drug treatments
Immune cells offer insights on billion-dollar virus
A functionally integrated cross-tissue alternative splicing program during short-term calorie restriction
Dietary oxidized plant sterol shifts macrophage state to fuel aortic inflammation
Unlocking the past – new method helps gain insights into old tissue
Novel AI model trained on RNA-Seq data accurately detects key gene mutations and predicts biomarkers across 32 cancer types
Transcriptomic aging clock reveals age-related molecular patterns in opioid dependence
RNA sequencing helps predict stem cell transplant benefit in pediatric AML
Protein ‘switch’ determines whether liposarcoma cells will become aggressive
Precursor tRNAs sense temperature changes: heat stress-induced capped pre-tRNAs suppress protein synthesis
Ketamine increases neuroplasticity in female mice but not in males
Somatic mutations linked to vascular damage in progeria
Scientists map dormant cancer cells’ hideouts, opening new targets for treatment
Soluble signals released by neighboring cells direct how the human kidney is built
Genetics influence how cancer arises – and how it evolves
RNA-based testing uncovers extraordinary diversity in mutations driving lung cancer
Study offers new insights into why ex-smokers remain at elevated risk of lung disease
Learning the grammar of gene regulation
New findings could transform new treatment for rare brain tumor astroblastoma
Stay Connected
Submit a Post to the Blog
Recent Posts
Subscribe to the RNA-Seq Blog
RNA-Seq Products & Services